Avastin v. Lucentis Trial Hits Snag: Co-Pays Essentially Unblind NIH Study
Executive Summary
In addition to roiling physicians and patients, the cost disparity between Lucentis (ranibizumab) and Avastin (bevacizumab) may also be undermining the study design of a head-to-head comparison of the two Genentech drugs, the lead investigator says